Dr Reddy’s Laboratories’ consolidated net profit declined by 86 per cent to ₹220 crore in the fourth quarter of last financial year ended March 31, 2026 compared to ₹1593 crore in the corresponding quarter of the previous year.
The total revenue of the Hyderabad-based company decreased by 12 per cent at ₹7561 crore in the quarter under review against ₹8506 crore in the year-ago period.
“Our performance this year reflects the impact of lower lenalidomide sales and several one-offs. The resilience of our branded businesses and currency tailwinds helped partially mitigate this impact,’’ G V Prasad, Co-Chairman & MD, Dr Reddy’s said in a release on Tuesday.
“We remain focused on strengthening our base business and improving margins, through cost efficiencies and portfolio optimization. In parallel, we continue to build long-term franchises in biosimilars, consumer health and innovation to deliver sustainable value,’’ he added.
Dr Reddy’s scrip fell 0.75 per cent on the Bombay Stock Exchange to end at ₹1270.10